FeesSafety
Pluang+

Pi Network's Mainnet upgrade activates but PI price stays below $0.08 amid unclear developer adoption.

Protocol Fundamentals
23 Oct 2026
Crypto news
View Source
Neutral
Pi Network's Mainnet upgrade activates but PI price stays below $0.08 amid unclear developer adoption.

Pi Network completed its scheduled Mainnet Protocol 28 upgrade around October 16, introducing improved tools for developers like better handling of delayed transactions and coordinated smart contract updates. Despite this, the PI token price remained below eight cents, trading near $0.0786 on October 23, with no clear price boost from the upgrade. The network reports over 300 Mainnet apps and 18.1 million KYC-verified users, but lacks detailed data on actual app usage or transaction volumes. The upcoming November 17-19 ecosystem summit may provide clearer evidence of developer adoption and economic activity on the network, which is crucial to assess the upgrade's real impact on PI demand and price.

The story on PI coin and its Protocol 28 upgrade comes with a snapshot of the broader cryptocurrency market on Pluang as of Oct 23, 2026 17:51 WIB. Out of 50 major cryptocurrencies priced on Pluang, 25 rose and 23 fell. Notable movers include Basic Attention Token (BAT) at Rp3.150 with a 2.35% increase and The Graph (GRT) at Rp436 with a 1.96% rise, while Fantom (FTM) dropped 2.05% to Rp11.382.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
18 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App